Seer Price to Sales Ratio 2020-2022 | SEER
Historical PS ratio values for Seer (SEER) over the last 10 years. The current P/S ratio for Seer as of July 01, 2022 is .
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Seer P/S Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Sales per Share | Price to Sales Ratio |
| 2022-07-01 | 9.81 | 60.94 | |
| 2022-03-31 | 15.24 | $0.16 | 94.68 |
| 2021-12-31 | 22.81 | $0.11 | 210.06 |
| 2021-09-30 | 34.53 | $0.07 | 477.76 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Biomedical and Genetics | $0.613B | $0.007B |
| Seer Inc. is a life sciences company. It engages in developing Proteograph(TM), which is an integrated solution consisting of consumables, automation instrumentation and proprietary software. Seer Inc. is based in REDWOOD CITY, Calif. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bristol Myers Squibb (BMY) | United States | $163.597B | 9.95 |
| Bio-Rad Laboratories (BIO.B) | United States | $14.907B | 32.33 |
| QIAGEN (QGEN) | Netherlands | $10.865B | 17.15 |
| Biohaven Pharmaceutical Holding (BHVN) | United States | $10.248B | 0.00 |
| Ginkgo Bioworks Holdings (DNA) | United States | $4.228B | 0.00 |
| Arcus Biosciences (RCUS) | United States | $1.901B | 48.18 |
| Emergent Biosolutions (EBS) | United States | $1.599B | 6.85 |
| Myovant Sciences (MYOV) | United Kingdom | $1.236B | 0.00 |
| Zymeworks (ZYME) | Canada | $0.320B | 0.00 |
| Gelesis Holdings (GLS) | United States | $0.114B | 0.00 |
| Enzo Biochem (ENZ) | United States | $0.104B | 0.00 |
| Ambrx Biopharma (AMAM) | United States | $0.103B | 0.00 |
| SQZ Biotechnologies (SQZ) | United States | $0.087B | 0.00 |
| ADC Therapeutics SA (ADCT) | Switzerland | $0.000B | 0.00 |
